We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insights Into Sotera Health (SHC) Q4: Wall Street Projections for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Sotera Health Company (SHC - Free Report) to post quarterly earnings of $0.21 per share in its upcoming report, which indicates a year-over-year decline of 19.2%. Revenues are expected to be $290.59 million, down 6.3% from the year-ago quarter.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Sotera Health metrics that Wall Street analysts commonly model and monitor.
The average prediction of analysts places 'Net Revenues- Sterigenics' at $182.82 million. The estimate indicates a change of +6.2% from the prior-year quarter.
Analysts predict that the 'Net Revenues- Nelson Labs' will reach $55.49 million. The estimate indicates a change of -4.7% from the prior-year quarter.
According to the collective judgment of analysts, 'Net Revenues- Nordion' should come in at $53.25 million. The estimate indicates a change of -33.3% from the prior-year quarter.
It is projected by analysts that the 'Segment Income- Sterigenics' will reach $101.07 million. Compared to the current estimate, the company reported $94.75 million in the same quarter of the previous year.
Analysts' assessment points toward 'Segment Income- Nelson Labs' reaching $17.87 million. Compared to the present estimate, the company reported $18.68 million in the same quarter last year.
Based on the collective assessment of analysts, 'Segment Income- Nordion' should arrive at $33.55 million. The estimate compares to the year-ago value of $53.32 million.
Shares of Sotera Health have demonstrated returns of -1% over the past month compared to the Zacks S&P 500 composite's -0.5% change. With a Zacks Rank #4 (Sell), SHC is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Insights Into Sotera Health (SHC) Q4: Wall Street Projections for Key Metrics
Wall Street analysts expect Sotera Health Company (SHC - Free Report) to post quarterly earnings of $0.21 per share in its upcoming report, which indicates a year-over-year decline of 19.2%. Revenues are expected to be $290.59 million, down 6.3% from the year-ago quarter.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Sotera Health metrics that Wall Street analysts commonly model and monitor.
The average prediction of analysts places 'Net Revenues- Sterigenics' at $182.82 million. The estimate indicates a change of +6.2% from the prior-year quarter.
Analysts predict that the 'Net Revenues- Nelson Labs' will reach $55.49 million. The estimate indicates a change of -4.7% from the prior-year quarter.
According to the collective judgment of analysts, 'Net Revenues- Nordion' should come in at $53.25 million. The estimate indicates a change of -33.3% from the prior-year quarter.
It is projected by analysts that the 'Segment Income- Sterigenics' will reach $101.07 million. Compared to the current estimate, the company reported $94.75 million in the same quarter of the previous year.
Analysts' assessment points toward 'Segment Income- Nelson Labs' reaching $17.87 million. Compared to the present estimate, the company reported $18.68 million in the same quarter last year.
Based on the collective assessment of analysts, 'Segment Income- Nordion' should arrive at $33.55 million. The estimate compares to the year-ago value of $53.32 million.
View all Key Company Metrics for Sotera Health here>>>
Shares of Sotera Health have demonstrated returns of -1% over the past month compared to the Zacks S&P 500 composite's -0.5% change. With a Zacks Rank #4 (Sell), SHC is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>